Dr. Lavina Bharwani received her Bachelor’s Degree with honors from Bryn Mawr College, USA. She received her MD from Baylor College of Medicine, USA in 1997. She completed her residency training in Internal Medicine, as well as her Hematology/Oncology fellowship training at Baylor College of Medicine in Houston, Texas. She is American Board Certified in Internal Medicine, Hematology and Medical Oncology. In 2000, at the end of her internal medicine residency, she received the Eli Lilly Award (Award for Humanistic attributes and special relationships with patients) at Baylor College of Medicine. During her last year of fellowship; she worked under the direction of Dr. Kent Osborne and Dr. Rachel Schiff of the Breast Center at Baylor College of Medicine to study the mechanisms of endocrine resistance in breast cancer tumors via the HER2/EGFR pathways. In 2003, Dr. Bharwani joined the faculty as an Assistant Professor of Medicine in the Division of Hematology/Oncology at Baylor College of Medicine.
Dr. Lavina Bharwani moved to Singapore in 2006 and joined Johns Hopkins Singapore IMC/TTSH as a Consultant in Medical Oncology. She is also an Assistant Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Bharwani has been involved in the development of educational programs at Johns Hopkins Singapore IMC /TTSH medical oncology department. Dr. Bharwani has been the Head of Department of the Medical Oncology Department since November 2017. She is also Adjunct Associate Professor/Lead of Medical Oncology at the Lee Kong Chian School of Medicine. She received the 2013 NHG Outstanding Education Partners Award. Dr Bharwani has also been involved in the development of the oncology services at TTSH and received the MyCare Recognition Award in 2010 by TTSH. She continues to help to develop medical oncology services throughout the NHG Cluster.
Dr. Bharwani’s area of interest includes breast cancer, gynecologic and gastrointestinal malignancies and has been a principal and co-investigator on a number of Phase II and Phase III clinical trials.